Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials
- 142 Downloads
In patients with acute coronary syndrome (ACS), the incidence of atrial fibrillation (AF) ranges from 10 to 21% and is an independent predictor of poor long-term outcomes including death [1, 2]. The choice of antithrombotic therapy for AF patients with concomitant ACS or patients who have undergone percutaneous coronary intervention (PCI) with coronary stenting is challenging . Dual antiplatelet therapy is indicated to reduce cardiovascular ischemic events including stent thrombosis, and is not proven to protect against AF-related strokes . In contrast, oral anticoagulation is proven to prevent ischemic stroke and systemic embolism in patients with AF but has not been shown to reduce stent thrombosis . However, triple therapy with dual antiplatelets and an anticoagulant increases the risk of bleeding . Therefore, alternative strategies to balance the risk of bleeding and ischemic events in this high-risk population is needed. Although previous trials have shown a...
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 2.January C, Wann L, Calkins H et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart R. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2019.01.011 Google Scholar
- 5.Brok J, Thorlund K, Wetterslev J, Gluud C (2009) Apparently conclusive meta-analyses may be inconclusive–trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 38:287–298. https://doi.org/10.1093/ije/dyn188 CrossRefGoogle Scholar
- 11.Lip G, Collet J, Haude M et al (2019) 2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the Europ. Europace 21:192–193CrossRefGoogle Scholar